Inozyme Pharma, Inc.

Inozyme Pharma, Inc. insiders are currently net buyers of INZY stock, showing bullish sentiment over the past 90 days. Executives have purchased $104.1M while selling $7.9M, resulting in a positive net flow of $96.2M. This buying activity represents 93% of total transaction volume.

Inozyme Pharma, Inc. has 32 active insiders who have filed SEC Form 4 transactions in the past 90 days. Robert Lorne Hopfner (Executive) leads with 13 transactions totaling $34.2M. Holdings A/s Novo (Executive) follows with 3 transactions worth $13.9M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Inozyme Pharma, Inc.'s current score of 93/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $104.1M in purchases versus $7.9M in sales.

The most recent insider transaction occurred on Jul 1, 2025, when Lorne Hopfner Robert (Executive) disposed of 1,571,741 shares at $4.00 per share for $6.3M. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, INZY insider trading sentiment is currently bullish with an Alignment Score of 93/100. The net insider flow of $96.2M reflects accumulation, with 93% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Inozyme Pharma, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At INZY, we track all Form 4 filings—currently showing 87 transactions from 32 insiders over 90 days.

A 10b5-1 plan allows Inozyme Pharma, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At INZY, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at INZY appears discretionary, making insider signals more meaningful.

You can monitor Inozyme Pharma, Inc. (INZY) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 32 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Inozyme Pharma, Inc.'s current score of 93/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $104.1M in purchases versus $7.9M in sales over 90 days, resulting in a net flow of $96.2M.

SEC Form 4 filings are mandatory reports that Inozyme Pharma, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At INZY, the most common type is "P" with 18 occurrences. The most recent Form 4 was filed on Jul 1, 2025 by Lorne Hopfner Robert.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Inozyme Pharma, Inc., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at INZY represents discretionary decisions with more informational value.